Document is current
Any future updates will be listed below
-
Authors
Shibata, Yuka
Kiyose, Toshiki
Himeno, Tatsuhito https://orcid.org/0000-0002-5677-1125
Shimoda, Masahiro
Ando, Hirohiko
Ito, Ayako
Itani, Atsuo
Shimizu, Toru
Miura, Rion
Matsuoka, Mika
Tsuzuki, Kento
Shinozaki, Takahiro
Motegi, Mikio
Hayami, Tomohide
Nakai-Shimoda, Hiromi
Kato, Makoto
Miura-Yura, Emiri
Nakayama, Takayuki
Morishita, Yoshiaki
Kondo, Masaki
Tsunekawa, Shin
Nakamura, Jiro
Amano, Tetsuya
Kamiya, Hideki
- License Information
-
More Information
Article History
Received: 26 September 2025
Accepted: 10 December 2025
First Online: 21 January 2026
Declarations
:
: Hideki Kamiya has received speaker honoraria from Abbott Japan LLC., Arkray Inc., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Eisai Co., Ltd., Fukuda Denshi Co., Ltd., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc.; and grant support from Nippon Boehringer Ingelheim Co., Ltd., CBC Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Fukuda Denshi Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Parexel International Corp., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Tatsuhito Himeno has received speaker honoraria from Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Fukuda Denshi Co., Ltd., Kowa Co., Ltd., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., and grant support from Nippon Boehringer Ingelheim Co., Ltd., CBC Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Fukuda Denshi Co., Ltd., Kissei Pharmaceutical Co., Ltd. Kowa Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Parexel International Corp., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Makoto Kato has received honoraria for lectures from Kowa Company, Ltd. and Taisho Pharmaceutical Co., Ltd. Emiri Miura-Yura has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kowa Company, Ltd., Taisho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nankodo Co., Ltd., SHINDAN TO CHIRYO SHA, Inc., Japan Medical Journal., Novo Nordisk Pharma Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd. Ayako Ito has received honoraria for a presentation from Kyowa Kirin Co., Ltd. Mikio Motegi has received grant or honoraria from The 24th Japan Medical Congress Memorial Medical Promotion Fund and Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Novartis Pharma K.K., and Novo Nordisk Pharma Ltd. Shin Tsunekawa has received grant support from the Japan Agency for Medical Research and Development. Toshiki Kiyose has received honoraria for a presentation from Kowa Company, Ltd. Yuka Shibata, Masahiro Shimoda, Hirohiko Ando, Atsuo Itani, Toru Shimizu, Rion Miura, Mika Matsuoka, Kento Tsuzuki, Takahiro Shinozaki, Tomohide Hayami, Hiromi Nakai-Shimoda, Makoto Kato, Takayuki Nakayama, Yoshiaki Morishita, Masaki Kondo, Tetsuya Amano, and Jiro Nakamura declare that they have no conflict of interest.
: The study was approved by the ethics committee on September 26, 2022.
